| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/MOL.54.1.94 |
| P698 | PubMed publication ID | 9658194 |
| P2093 | author name string | J Goldfarb | |
| P Leff | |||
| W P Clarke | |||
| K A Berg | |||
| S Maayani | |||
| C Scaramellini | |||
| P433 | issue | 1 | |
| P921 | main subject | serotonin | Q167934 |
| P304 | page(s) | 94-104 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus | |
| P478 | volume | 54 |
| Q34119175 | 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens |
| Q35879418 | 5-Hydroxytryptamine 5HT2C receptors form a protein complex with N-methyl-D-aspartate GluN2A subunits and activate phosphorylation of Src protein to modulate motoneuronal depolarization |
| Q92495421 | A Machine Learning Approach for the Discovery of Ligand-Specific Functional Mechanisms of GPCRs |
| Q37323369 | A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation |
| Q28249697 | A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2 |
| Q47583813 | A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration |
| Q35531857 | A novel method for analyzing extremely biased agonism at G protein-coupled receptors |
| Q39164871 | A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment |
| Q41818303 | Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins |
| Q35108160 | Activation, internalization, and recycling of the serotonin 2A receptor by dopamine. |
| Q34122643 | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development |
| Q28235776 | Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats |
| Q44583796 | Agonist function of the neurokinin receptor antagonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, in monocytes |
| Q28361199 | Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells |
| Q24323261 | Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells |
| Q43670357 | Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells |
| Q44400220 | Agonist-specific coupling of a cloned human α1A-adrenoceptor to different second messenger pathways |
| Q35188110 | Allosteric modulation of the M₃ muscarinic receptor by amiodarone and N-ethylamiodarone: application of the four-ligand allosteric two-state model |
| Q37416470 | Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. |
| Q24646463 | Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells |
| Q33865206 | Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. |
| Q35720141 | An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. |
| Q42024387 | An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFalpha up-regulates 5-HT(2A)-mediated contraction |
| Q64116370 | An intact model for quantifying functional selectivity |
| Q41869522 | An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins |
| Q44366984 | Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety |
| Q39749438 | Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. |
| Q24647492 | Arresting serotonin |
| Q37622283 | Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. |
| Q36160942 | Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors |
| Q35153734 | Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors |
| Q40420767 | Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. |
| Q58695932 | Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction |
| Q40809869 | Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism |
| Q59791974 | Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines |
| Q35045194 | Cardiac-specific overexpression of human beta2 adrenoceptors in mice exposes coupling to both Gs and Gi proteins |
| Q38429080 | Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development |
| Q28344079 | Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors |
| Q43757440 | Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation. |
| Q35284832 | Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain |
| Q35078148 | Co-expression of GRK2 reveals a novel conformational state of the µ-opioid receptor |
| Q42054049 | Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells |
| Q37024485 | Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open |
| Q42524236 | Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. |
| Q42084998 | Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation |
| Q44612076 | Co‐ordinated expression of 5‐HT2C receptors with the NCX1 Na+/Ca2+ exchanger in histaminergic neurones |
| Q44121972 | Cyclooxygenase inhibitor modulation of dopamine-related behaviours |
| Q34967589 | D2-like receptor activation does not initiate a brain docosahexaenoic acid signal in unanesthetized rats |
| Q92455368 | Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity |
| Q44513544 | Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment |
| Q52538240 | Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial cells. |
| Q77375698 | Dissecting intracellular signaling pathways with membrane-permeable peptides |
| Q46934804 | Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats |
| Q28584067 | Distinct regions of C-terminus of the high affinity neurotensin receptor mediate the functional coupling with pertussis toxin sensitive and insensitive G-proteins |
| Q33619504 | Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR) |
| Q34099978 | Diverse signalling by 5-hydroxytryptamine (5-HT) receptors |
| Q35448857 | Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission |
| Q82029300 | Dopamine receptor pharmacology |
| Q34070870 | Dopamine receptors: from structure to behavior |
| Q39635515 | Dual Neuroprotective and Neurotoxic Effects of Cannabinoid Drugs in Vitro |
| Q33942739 | Editing of neurotransmitter receptor and ion channel RNAs in the nervous system |
| Q33739391 | Efficacy in drug receptor theory: outdated concept or under-valued tool? |
| Q46457347 | Endogenous lysophosphatidic acid (LPA1 ) receptor agonists demonstrate ligand bias between calcium and ERK signalling pathways in human lung fibroblasts. |
| Q90115188 | Essential fatty acids and Barratt impulsivity in gambling disorder |
| Q40573150 | Essential role for phosphatidylinositol 4,5-bisphosphate in the expression, regulation, and gating of the slow afterhyperpolarization current in the cerebral cortex. |
| Q46240693 | Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles |
| Q42521477 | Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits |
| Q45100662 | Expression of α(1)-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT(2A) receptors |
| Q35072763 | Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications |
| Q35999789 | Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. |
| Q48656806 | Functional Selectivity and Biased Receptor Signaling |
| Q22242288 | Functional Selectivity and Classical Concepts of Quantitative Pharmacology |
| Q24675490 | Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells |
| Q40663313 | Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity |
| Q39021630 | Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets |
| Q39378056 | Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors |
| Q38017282 | Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics. |
| Q37337832 | Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor |
| Q28350001 | G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype |
| Q35566599 | G-protein-coupled receptors: past, present and future. |
| Q40589951 | Galpha protein selectivity determinant specified by a viral chemokine receptor-conserved region in the C tail of the human herpesvirus 8 g protein-coupled receptor |
| Q40842125 | Gbetagamma subunit combinations differentially modulate receptor and effector coupling in vivo |
| Q33714695 | Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity |
| Q34093269 | Gonadotropin-releasing hormone receptor-coupled gene network organization |
| Q36440378 | Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors |
| Q22251224 | Hallucinogens |
| Q39414464 | Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways |
| Q24595389 | Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model |
| Q38199134 | Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands |
| Q44317346 | Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). |
| Q44464149 | Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats |
| Q37237548 | Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice |
| Q48292762 | In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain |
| Q28582209 | Integrins regulate opioid receptor signaling in trigeminal ganglion neurons |
| Q42048502 | Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity |
| Q35156390 | Interleukin-6 attenuates serotonin 2a receptor signaling by activating the JAK-STAT pathway |
| Q37778511 | Inverse Agonism at Serotonin and Cannabinoid Receptors |
| Q37834732 | Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation |
| Q42369139 | Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex |
| Q38200427 | Ligand bias prevents class equality among beta-blockers. |
| Q33952880 | Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling |
| Q35181787 | Ligand-selective receptor conformations revisited: the promise and the problem |
| Q26850084 | Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade |
| Q58798205 | Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity |
| Q37610141 | Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. |
| Q31031906 | Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response |
| Q42592784 | Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz |
| Q38295552 | Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction |
| Q36880896 | Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. |
| Q38101499 | Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology |
| Q34360861 | N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). |
| Q36012336 | Native serotonin membrane receptors recognize 5-hydroxytryptophan-functionalized substrates: enabling small-molecule recognition. |
| Q90162784 | Natural Psychoplastogens As Antidepressant Agents |
| Q34354034 | Neurokinin B and the hypothalamic regulation of reproduction |
| Q34358365 | New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454. |
| Q38044984 | New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. |
| Q37822833 | New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma |
| Q44087155 | Nitric oxide signalling by selective beta(2)-adrenoceptor stimulation prevents ACh-induced inhibition of beta(2)-stimulated Ca(2+) current in cat atrial myocytes |
| Q42656342 | Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells |
| Q27305182 | Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism |
| Q24681087 | Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? |
| Q37078169 | On the analysis of ligand-directed signaling at G protein-coupled receptors |
| Q37784750 | Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs |
| Q42447404 | Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. |
| Q33677059 | Partial agonists and G protein-coupled receptor desensitization |
| Q43264414 | Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions |
| Q37014106 | Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior. |
| Q32077960 | Pharmacological characterisation of human 5-HT2 receptor subtypes |
| Q40749145 | Pharmacological characterisation of the goldfish somatostatin sst5 receptor |
| Q24321902 | Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors |
| Q73082196 | Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor |
| Q30544127 | Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine]. |
| Q36574422 | Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex |
| Q35140840 | Predicting therapeutic value in the lead optimization phase of drug discovery |
| Q78339333 | Protean behavior by agonists: agonist-directed trafficking of receptor signaling |
| Q30359998 | Psychedelics |
| Q28142282 | Qualitative and quantitative assessment of relative agonist efficacy |
| Q35188090 | Quantifying ligand bias at seven-transmembrane receptors. |
| Q34187552 | Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT2A or 5-HT2C receptors |
| Q33251617 | Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries |
| Q28359232 | RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity |
| Q35693323 | Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology |
| Q35996747 | Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations |
| Q34467007 | Regulation of 5-HT(1A) and 5-HT(1B) receptor systems by phospholipid signaling cascades |
| Q36005496 | Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane |
| Q37602790 | Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice |
| Q44628581 | Selective Interaction of ARF1 with the Carboxy-Terminal Tail Domain of the 5-HT2A Receptor |
| Q42021865 | Selective mode of action of guanidine-containing non-peptides at human NPFF receptors |
| Q42356975 | Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero |
| Q52659069 | Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. |
| Q36396444 | Serotonin 2a Receptor and Serotonin 1a Receptor Interact Within the Medial Prefrontal Cortex During Recognition Memory in Mice |
| Q37351035 | Serotonin 5-HT2 receptors induce a long-lasting facilitation of spinal reflexes independent of ionotropic receptor activity. |
| Q34048779 | Serotonin 5-HT2C receptor protein expression is enriched in synaptosomal and post-synaptic compartments of rat cortex |
| Q38600048 | Serotonin and brain function: a tale of two receptors |
| Q33874819 | Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction |
| Q31882878 | Serotonin excites tuberomammillary neurons by activation of Na(+)/Ca(2+)-exchange. |
| Q34402623 | Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo |
| Q36126606 | Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. |
| Q33890786 | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery |
| Q38081692 | Signalling bias in new drug discovery: detection, quantification and therapeutic impact. |
| Q41906281 | Signalling profile differences: paliperidone versus risperidone |
| Q28346498 | Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides |
| Q28289039 | Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors |
| Q36237653 | Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists |
| Q42316573 | Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach. |
| Q37230848 | Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. |
| Q91749643 | Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development |
| Q33985759 | Teaching old receptors new tricks: biasing seven-transmembrane receptors |
| Q39924947 | The Gq and G12 families of heterotrimeric G proteins report functional selectivity |
| Q28204452 | The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways |
| Q38287845 | The activity of the serotonin receptor 2C is regulated by alternative splicing |
| Q24645656 | The behavioral pharmacology of hallucinogens |
| Q62373349 | The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors |
| Q37131419 | The origins of diversity and specificity in g protein-coupled receptor signaling |
| Q34402658 | The potential for selective pharmacological therapies through biased receptor signaling |
| Q37175429 | The single kinin receptor signals to separate and independent physiological pathways in Malpighian tubules of the yellow fever mosquito |
| Q74818904 | Theoretical implications of receptor coupling to multiple G proteins based on analysis of a three-state model |
| Q36773331 | Therapeutic potential of β-arrestin- and G protein-biased agonists. |
| Q35012574 | Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? |
| Q40629393 | Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex |
| Q38976185 | UTP is not a biased agonist at human P2Y(11) receptors |
| Q28483679 | VENNTURE--a novel Venn diagram investigational tool for multiple pharmacological dataset analysis |
| Q40034384 | beta-arrestin-biased agonism at the beta2-adrenergic receptor |
Search more.